Matilde Inglese
Overview
Explore the profile of Matilde Inglese including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
265
Citations
5774
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Costa V, Aluan K, Schiavetti I, Bason C, Vigo T, Leveraro E, et al.
PLoS One
. 2025 Feb;
20(2):e0311214.
PMID: 40014609
Background: Multiple Sclerosis (MS) is the first cause of non-traumatic neurological disability in young adults. Primary and secondary progressive MS are still lacking effective treatments. A new nutraceutical product made...
2.
Tacchino A, Ponzio M, Confalonieri P, Leocani L, Inglese M, Centonze D, et al.
JMIR Res Protoc
. 2025 Feb;
14:e58026.
PMID: 39899835
Background: Physical activity (PA) has been recommended in multiple sclerosis (MS) to maintain good physical fitness and mental health, reduce the severity of symptoms and risk of relapse, and improve...
3.
Filippi M, Amato M, Avolio C, Gallo P, Gasperini C, Inglese M, et al.
J Neurol
. 2025 Feb;
272(2):179.
PMID: 39891770
The classification of multiple sclerosis (MS) into the two distinct phases of relapsing-remitting and progressive, including primary progressive and secondary progressive phenotypes (PPMS and SPMS, respectively) has long been accepted;...
4.
Boccia V, Leveraro E, Cipriano E, Lapucci C, Sirito T, Cellerino M, et al.
J Neurol Neurosurg Psychiatry
. 2025 Jan;
PMID: 39890460
Background: High-efficacy disease-modifying therapies (HETs) have substantially improved multiple sclerosis (MS) management, yet ongoing cognitive decline remains a concern. This study aims to assess Symbol Digit Modalities Test (SDMT) changes...
5.
de Meo E, Portaccio E, Cortese R, Ruano L, Goretti B, Niccolai C, et al.
Ann Clin Transl Neurol
. 2025 Jan;
PMID: 39861952
Objectives: We aim to investigate cognitive phenotype distribution and MRI correlates across pediatric-, elderly-, and adult-onset MS patients as a function of disease duration. Methods: In this cross-sectional study, we...
6.
Tecchio F, Bertoli M, Sbragia E, Stara S, Pasqualetti P, LAbbate T, et al.
Mult Scler Relat Disord
. 2025 Jan;
94:106276.
PMID: 39842388
Background: A recent application of the GRADE guidelines indicated Faremus, a 5-day neuromodulation for 15 min per day via transcranial direct current stimulation (tDCS), as medium to highly recommendable for...
7.
Silvestri G, Roccatagliata L, Tazza F, Schiavi S, Coccia A, Bandettini Di Poggio M, et al.
Headache
. 2025 Jan;
PMID: 39834045
Objective: To investigate, in two cohorts including patients with multiple sclerosis (MS) and migraine, (i) the prevalence of the "central vein sign" (CVS), (ii) the spatial distribution of positive CVS...
8.
Muraro P, Mariottini A, Greco R, Burman J, Iacobaeus E, Inglese M, et al.
Nat Rev Neurol
. 2025 Jan;
21(3):140-158.
PMID: 39814869
Autologous haematopoietic stem cell transplantation (AHSCT) is a treatment option for relapsing forms of multiple sclerosis (MS) that are refractory to disease-modifying therapy (DMT). AHSCT after failure of high-efficacy DMT...
9.
Zanghi A, Fantozzi R, Foschi M, Signoriello E, Inglese M, Lus G, et al.
Ther Adv Neurol Disord
. 2025 Jan;
18():17562864241304212.
PMID: 39803327
Background: Characterizing Cladribine tablets prescription pattern in daily clinical practice is crucial for optimizing multiple sclerosis (MS) treatment. Objectives: To describe efficacy, safety profile and new disease-modifying therapy (DMT) prescriptions...
10.
Cipriano E, Boffa G, Graziano N, Wigley C, Petracca M, Schiavi S, et al.
Brain Commun
. 2025 Jan;
7(1):fcae446.
PMID: 39763635
Sodium MRI can measure sodium concentrations in people with multiple sclerosis, but the extent to which these alterations reflect metabolic dysfunction in the absence of tissue damage or neuroaxonal loss...